Cover Image for T2B September Comm Convo: Beyond the Binder in the Era of Constant Crisis
Cover Image for T2B September Comm Convo: Beyond the Binder in the Era of Constant Crisis
Private Event

T2B September Comm Convo: Beyond the Binder in the Era of Constant Crisis

Hosted by Ticket to Biotech
Zoom
Get Tickets
Approval Required
Your registration is subject to host approval.
Ticket Price
$40.00
Welcome! To join the event, please get your ticket below.
About Event

***If you do not receive your event confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the Zoom info and cal invite.***


Comm Convo pricing:

  • Complimentary for T2B Pro and Student community members (log into your T2B account and access your promo code here)

  • $40 for Basic members (access to live event only, not the recording)

If you're not part of Ticket to Biotech, confirm you're eligible, and join before registering for this event:

Request to join T2B


COMM CONVO: BEYOND THE BINDER IN THE ERA OF CONSTANT CRISIS

Crisis readiness carries new weight as political volatility, regulatory shifts, and the speed of social media compress the time between incidents. We're the ones building plans, briefing leadership, and making real-time calls when the traditional scenario-planning binder doesn't match the moment. Traditional crisis plans assume a beginning and an end, though today's environment rarely offers either. This Comm Convo opens a candid conversation about readiness in an age of constant crisis, from real-time decision-making to sustaining teams when there is no recovery period between incidents.

WHY ATTEND

  • Discuss how to brief executives and boards on fast-moving decisions when full information is not yet available and the stakes shift sometimes minute to minute.

  • Explore ways to align medical, legal, regulatory, and communications teams quickly when a crisis outpaces the standard approval chain.

  • Share tactics for building organizational muscle memory so teams can respond with confidence without a written playbook for the exact moment.

  • Consider what constant crisis means for industry credibility and public trust, particularly heading into an active election season.

FEATURED SPEAKERS

  • Stephen Majors, VP, Global Communications and Investor Relations, Alliance for Regenerative Medicine

  • Adam Silverstein, Managing Director, Narrative Strategies

MEET OUR SPEAKERS

Stephen Majors, VP, Global Communications and Investor Relations, Alliance for Regenerative Medicine

Each step of Stephen’s 15-year career converged at ARM in his role of Vice President of Communications: A journalist covering politics and state legislatures; a business development professional advising companies on how to navigate geopolitical risk; a pharma and biotech industry consultant; a graduate of journalism and public policy programs.

At ARM, Stephen serves as global media spokesperson and social media strategist and contributes to ARM’s policy and advocacy objectives in Washington, state capitals, and Brussels. He breaks down complex science for the public and policymakers and explains why policies need to change to ensure that patients can benefit from the groundbreaking advancements of ARM’s members.

Stephen thought he left science behind after muddling his way through AP Chemistry in high school. He’s glad he was wrong.

Adam Silverstein, Managing Director, Narrative Strategies

Adam is a Managing Director in Narrative’s New York office. In this role, Adam counsels a wide range of clients across the healthcare sector, with a focus on pharmaceutical and biotechnology companies.

Adam brings nearly two decades of agency experience in healthcare communications, public relations, and thought leadership. He joins Narrative from Scient Public Relations, where he served as Head of Media Relations & Thought Leadership, advising C-suite leaders and corporate affairs teams on corporate reputation, media strategy, and complex scientific communications. Earlier in his career, Adam held roles of increasing seniority at Edelman and Fleishman Hillard, advising pharmaceutical and biotechnology companies ranging from startups to Fortune 500 organizations.

His work spans companies’ most critical moments, including clinical data, regulatory milestones, executive transitions, and sensitive corporate issues. Over the course of his career, Adam has helped executives build lasting relationships with the journalists covering their companies and industries. He operates as a trusted, embedded partner to executive and R&D leadership teams, as well as the reporters who cover their organizations. He takes a modern approach to media relations that incorporates AI/LLMs into message development and measurement, media strategy, and executive communications.

Adam is a lifelong, mostly hopeless fan of the New York Mets. He lives in New Jersey with his wife, daughter, and son. Adam earned his B.A. from the University of Delaware.